section name header

Pronunciation

tha-LID-oh-mide

Classifications

Therapeutic Classification: Immunosuppressant agents

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 67–93% absorbed following oral administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Hydrolyzed in plasma to multiple metabolites. Primarily excreted in the urine (92%; <4% as unchanged drug).

Half-life: 5–7 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2–5 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: bradycardia, edema, orthostatic hypotension, thromboembolic events ( risk with dexamethasone in multiple myeloma).

Derm: drug reaction with eosinophilia and systemic symptoms (dress), rash, stevens-johnson syndrome, toxic epidermal necrolysis, photosensitivity.

GI: constipation.

Hemat: neutropenia, thrombocytopenia.

Neuro: dizziness, drowsiness, peripheral neuropathy, seizures.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS , TUMOR LYSIS SYNDROME.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Erythema Nodosum Leprosum

Multiple Myeloma

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Thalomid